Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
Charles River Laboratories International $1 billion senior notes offering
We advised Charles River Laboratories on the high-yield debt offering
Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Anthem $3.5 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
Illumina $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
MediaAlpha $370.3 million secondary offering
We advised the underwriters on the SEC-registered stock offering
Oncopeptides SEK 1.1 billion private placing of new shares
We advised Oncopeptides on the private placement of shares
Oak Street Health $920 million convertible senior notes offering
We advised the initial purchasers on the Rule 144A offering
Prometheus Biosciences $218.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing